Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21282227 | 0.82 | TAAR1 (0.71) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| SCHEMBL15679325 | 0.66 | TAAR1 (0.78) | TAAR1DRD2HTR1AHTR7DRD3 | |
| SCHEMBL14903735 | 0.66 | TAAR1 (0.74) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| SCHEMBL28758384 | 0.65 | SLC6A2 (0.40) | — | |
| Ulotaront SCHEMBL14903737 | 0.65 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| SCHEMBL14903754 | 0.65 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| Ulotaront SCHEMBL12644523 | 0.65 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| Ulotaront SCHEMBL14903727 | 0.65 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| SCHEMBL14903730 | 0.64 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 | |
| SCHEMBL14903739 | 0.64 | TAAR1 (1.00) | TAAR1DRD2HTR1AHTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854791-B1 | NOVEL THIOPHENE COMPOUND AND PROCESS FOR PRODUCING CAFFENOFURAN OR ANALOGUE THEREOF FROM THE SAME | SAN EI GEN FFI INC (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1854791-A1 | NOVEL THIOPHENE COMPOUND AND PROCESS FOR PRODUCING CAFFENOFURAN OR ANALOGUE THEREOF FROM THE SAME | SAN-EI GEN F.F.I., INC. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | CYP4F3, CBR3, GTF3C4 | TAAR1 255/4885DRD2 131/4885HTR1A 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.